TRANSPERS News: 2024 in Review and Two JAMA Publications Generate Wide Interest
Letter from Center Director
Happy 2025! I’d like to thank the TRANSPERS team for a productive 2024, and I’m excited to continue our work in 2025. This newsletter highlights several impactful publications, collaborators in the news, a congratulations, and conference highlights.
Do you have an announcement you would like to see in our next newsletter? Let us know!
Kathryn
Year in Review: 2024
What's Coming Up: 2025
In 2025, we are continuing our work on:
- Expedited Regulatory Approval Pathways for Drugs and Diagnostics
- Model-based Outcomes for Geographic-based Health Outcomes
- Cost-effectiveness Across Different Populations
- Role of Independent Medical Review for Genetic Tests
- Financial Assistance Programs for Patients
2024 JAMA Publication On Blood Tests for Alzheimer’s Disease Generates Broad Interest
TRANSPERS Work on Multicancer Detection Tests Continues to be Widely Disseminated
Our work on coverage considerations for multicancer detection tests is in the top 1% for Almetric scores across all journals for that timeframe, illustrating that this work continues to generate wide interest across news and social media outlets.
TRANSPERS In the News
Long-time TRANSPERS colleague Allison Kurian was interviewed for an article in the Washington Post about genetic testing and its importance for cancer prevention, testing, and treatment.
Grace Lin was cited in a Council of State Governments Midwest story on states mandating that health plans cover biomarker testing, a topic Lin knows well and wrote about in a 2024 paper published in JAMA.
TRANSPERS Collaborator Deborah Marshall Receives Award
Conference Highlights: ISPOR 2024 and ACMG 2025
Join Emily Mrig at the 2025 ACMG Annual Clinical Genetics Meeting where she’ll present on “Participants' Experiences with and Perspectives on Genomic Research in an Undiagnosed Disease Program.” Register here.